fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Majority of children with spinal muscular atrophy treated with Evrysdi (risdiplam) are able to sit, stand and walk independently, two-year data demonstrate – Genentech/Roche

Written by | 21 Oct 2024

Genentech, a member of the Roche Group  presented positive 2-year data from the ongoing RAINBOWFISH study at the 29th World Muscle Society (WMS) Congress, October 8-12, 2024, assessing… read more.

Majority of newborn babies with spinal muscular atrophy (SMA) treated with Evrysdi (risdiplam) are able to sit independently after 1 year of treatment – Roche

Written by | 10 Oct 2023

Roche presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi (risdiplam) in babies with pre-symptomatic SMA (n=26), aged… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.